Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.
Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.
复制标题
DOI：
10.1038/s41598-021-85389-x
复制
发表时间：
2021-03-16
影响因子：
4.6
通讯作者：
Thomas K
中科院分区：
文献类型：
--
作者：
Cohen IV;Makunts T;Abagyan R;Thomas K
3，4-亚甲基二氧甲基苯丙胺(MDMA)目前正在接受美国食品和药物管理局(FDA)的评估，用于治疗创伤后应激障碍(PTSD)。如果MDMA是FDA批准的，了解哪些药物可能会造成药物相互作用的风险将是重要的。这项研究的目的是使用FDA的药物安全监测数据来评估单独或与其他常见药物和滥用药物联合服用MDMA所造成的风险。到目前为止，FDA已经收到了近1000份关于使用MDMA的报告。这些报告中的大多数包括协变量，如共同摄取的物质和人口统计参数。采用单变量和多变量Logistic回归分析MDMA使用者报告死亡风险的影响因素。几类药物(MDMA代谢物或类似物、麻醉药、肌肉松弛药、安非他明和兴奋剂、苯二氮卓、乙醇、阿片类药物)、四种抗抑郁药(安非他酮、舍曲林、文拉法辛和西酞普兰)和奥氮平显示报告的死亡风险的优势比增加。未来的药物-药物相互作用临床试验应该评估我们的结果中描述的任何其他药物-药物相互作用是否在受控医疗环境中实际上构成了发病率或死亡率的风险。
3,4-Methylenedioxymethamphetamine (MDMA) is currently being evaluated by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). If MDMA is FDA-approved it will be important to understand what medications may pose a risk of drug–drug interactions. The goal of this study was to evaluate the risks due to MDMA ingestion alone or in combination with other common medications and drugs of abuse using the FDA drug safety surveillance data. To date, nearly one thousand reports of MDMA use have been reported to the FDA. The majority of these reports include covariates such as co-ingested substances and demographic parameters. Univariate and multivariate logistic regression was employed to uncover the contributing factors to the reported risk of death among MDMA users. Several drug classes (MDMA metabolites or analogs, anesthetics, muscle relaxants, amphetamines and stimulants, benzodiazepines, ethanol, opioids), four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated increased odds ratios for the reported risk of death. Future drug–drug interaction clinical trials should evaluate if any of the other drug–drug interactions described in our results actually pose a risk of morbidity or mortality in controlled medical settings.
登录
查看更多内容
影响因子：
4.4
作者：
Roxburgh, Amanda;Lappin, Julia
通讯作者：
Lappin, Julia
影响因子：
4.1
作者：
Saleemi, Sarah;Pennybaker, Steven J.;Johnson, Matthew W.
通讯作者：
Johnson, Matthew W.
DOI：
10.1017/s1461145713001132
发表时间：
2014-03-01
影响因子：
4.8
作者：
Hysek, Cedric M.;Simmler, Linda D.;Liechti, Matthias E.
通讯作者：
Liechti, Matthias E.
影响因子：
4.1
作者：
Liechti, ME;Vollenweider, FX
通讯作者：
Vollenweider, FX
影响因子：
4.1
作者：
Vizeli, Patrick;Liechti, Matthias E.
通讯作者：
Liechti, Matthias E.